Breast Cancer

Experimental drug shows promise killing triple negative breast cancer cells.

Little clinical data exists to aid shared decision making for mammography frequency.

Nebivolol shows promise blocking anthracycline-induced cardiotoxicity in breast cancer patients.

Patients with negative expectations about breast cancer treatment had nearly twice the amount of side effects.

Genetic mechanisms could potentially promote cancer growth and spread.

Expanded use of bundled payments in cancer for services such as mammography.

Some breast cancer tumors are not sensitive to Herceptin.

Duration and degree of being overweight impacts cancer risk in postmenopausal women.

Researchers examine whether cognitive impairment caused by chemotherapy drugs in breast cancer patients is a long-term issue.

Breast cancer patients who expected significant side effects from adjuvant hormone therapy reported worse adverse events.

Researchers advance understanding of how breast cancer drugs work inside human cells.

A consensus about margins could reduce healthcare costs for patients with ductal carcinoma in-situ.

Hormone receptor testing may be unnecessary in breast cancer patients.

Aromatase inhibitors in human estrogen-receptor positive breast cancer can cause tumor mutations.

Obesity becoming a growing health concern for cancer survivors, specifically breast and colorectal cancers.

Increased genetic knowledge about non-whites could lead to improved knowledge and treatments.

Bacterial differences were seen between tissue from patients with and without breast cancer.

Drug to be evaluated combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ribociclib seeking indication for use in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

The FDA has granted breakthrough therapy designation to Novartis's ribociclib (LEE011).

Eli Lily’s clinical trial for abemaciclib will continue as planned.

Updated criteria outlined by ASCO may lead to an increase in the number of breast cancers that test HER2-positive.

Certain mutations influence risk of drug resistance across several cancer types.

Hormones in body fat provide bridge between breast cancer and obesity.

Surgery is performed in a different position than pre-operative breast imaging MRIs.

Perceived memory problems could be linked to stress rather that treatment in breast cancer survivors.

Fluorescence lifetime imaging identifies which breast cancer patients will benefit from specific treatments.

Neratinib and the combination of veliparib plus carboplatin improves breast cancer outcomes.

Support groups and social networking help breast cancer patients manage emotions and stress.

Patients treated for high cholesterol showed improved survival in bowel, breast, lung, and prostate cancers.